{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:55:43Z","timestamp":1790837743180,"version":"4.1.0"},"reference-count":124,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Myositis-specific autoantibodies have long been used to classify patients into clinically meaningful subsets; however, recent studies show that the field is moving beyond the simple question of which autoantibody is present. This review examines how emerging specificities, epitope architecture, autoantibody coexistence, pathogenic mechanisms, and detection platforms are reshaping the interpretation of myositis serology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Recent work has expanded the autoantibody repertoire through the identification of additional autoantibody specificities, multiprotein antigenic complexes, and transcriptional regulators. At the same time, epitope-level studies reveal that patients sharing the same autoantibody specificity may recognize different antigenic regions, with potential implications for phenotype, prognosis, and assay interpretation. Evidence also challenges the view of myositis autoantibodies as passive biomarkers: selected specificities may mediate complement-dependent muscle injury, amplify inflammatory circuits, or interfere with intracellular antigen function. Meanwhile, new detection platforms have not only improved discovery but also exposed limitations related to conformational epitopes, cross-reactivity, false seronegativity, and assay standardization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Novelty in myositis autoantibodies should be understood not only as new targets but also as new paradigms linking antigen structure, immune mechanisms, detection methods, and clinical actionability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001195","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:01:49Z","timestamp":1790834509000},"page":"456-469","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Myositis autoantibodies: from new specificities to new paradigms"],"prefix":"10.1097","volume":"38","author":[{"given":"Andrea","family":"Aguilar-Vazquez","sequence":"first","affiliation":[{"name":"Instituto de Investigaci\u00f3n en Reumatolog\u00eda y del Sistema M\u00fasculo-Esquel\u00e9tico (IIRSME), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco"},{"name":"Estancias Posdoctorales por M\u00e9xico, Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Innovaci\u00f3n (SECIHTI), CDMX, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles S.","family":"Galindo-Feria","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Center for Molecular Medicine"},{"name":"Department of Gastroenterology, Dermatology and Rheumatology, Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"R1-20261001","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R2-20261001","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R3-20261001","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","article-title":"Description of a serological reaction characteristic of polymyositis","volume":"5","author":"Reichlin","year":"1976","journal-title":"Clin Immunol Immunopathol"},{"key":"R4-20261001","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/art.1780280711","article-title":"The association between Mi-2 antibodies and dermatomyositis","volume":"28","author":"Targoff","year":"1985","journal-title":"Arthritis Rheum"},{"key":"R5-20261001","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0161-5890(80)90109-1","article-title":"Purification and characterization of a nuclear nonhistone basic protein (Mi-1) which reacts with antiimmunoglobulin sera and the sera of patients with dermatomyositis","volume":"17","author":"Nishikai","year":"1980","journal-title":"Mol Immunol"},{"key":"R6-20261001","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/art.43038","article-title":"Clinical characteristics of anti-synthetase syndrome: analysis from the Classification Criteria for Anti-Synthetase Syndrome Project","volume":"77","author":"Faghihi-Kashani","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R7-20261001","doi-asserted-by":"crossref","first-page":"102951","DOI":"10.1016\/j.jaut.2022.102951","article-title":"Autoantigenic properties of the aminoacyl tRNA synthetase family in idiopathic inflammatory myopathies","volume":"134","author":"Preger","year":"2023","journal-title":"J Autoimmun"},{"key":"R8-20261001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11926-024-01171-8","article-title":"Newer autoantibodies and laboratory assessments in myositis","volume":"27","author":"Harvey","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"R9-20261001","doi-asserted-by":"crossref","first-page":"e0142253","DOI":"10.1371\/journal.pone.0142253","article-title":"Evaluation of multitRNA synthetase complex by multiple reaction monitoring mass spectrometry coupled with size exclusion chromatography","volume":"10","author":"Park","year":"2015","journal-title":"PLoS One"},{"key":"R10-20261001","doi-asserted-by":"crossref","first-page":"103204","DOI":"10.1016\/j.autrev.2022.103204","article-title":"Two novel antiaminoacyl tRNA synthetase antibodies: autoantibodies against cysteinyl-tRNA synthetase and valyl-tRNA synthetase","volume":"21","author":"Muro","year":"2022","journal-title":"Autoimmun Rev"},{"key":"R11-20261001","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2022-222686","article-title":"Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies","volume":"82","author":"Vulsteke","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R12-20261001","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1172\/JCI116493","article-title":"Reaction of anti-OJ autoantibodies with components of the multienzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase","volume":"91","author":"Targoff","year":"1993","journal-title":"J Clin Invest"},{"key":"R13-20261001","doi-asserted-by":"crossref","first-page":"152858","DOI":"10.1016\/j.semarthrit.2025.152858","article-title":"Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard: A systematic review and meta-analysis","volume":"75","author":"Gono","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"R14-20261001","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R15-20261001","doi-asserted-by":"crossref","first-page":"104094","DOI":"10.1016\/j.autrev.2026.104094","article-title":"Phage ImmunoPrecipitation sequencing (PhIP-Seq) in autoimmunity research: From high-resolution epitope mapping to multiomics integration","volume":"25","author":"Yu","year":"2026","journal-title":"Autoimmun Rev"},{"key":"R16-20261001","doi-asserted-by":"crossref","first-page":"121076","DOI":"10.1016\/j.cca.2026.121076","article-title":"Laboratory testing for antisynthetase antibodies: a novel algorithm to improve diagnostic accuracy","volume":"590","author":"Baucells","year":"2026","journal-title":"Clin Chim Acta"},{"key":"R17-20261001","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1172\/JCI81031","article-title":"Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies","volume":"125","author":"Albrecht","year":"2015","journal-title":"J Clin Invest"},{"key":"R18-20261001","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/kez406","article-title":"Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis","volume":"59","author":"Betteridge","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R19-20261001","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1093\/rheumatology\/keab846","article-title":"Association of anti-HSC70 autoantibodies with cutaneous ulceration and severe disease in juvenile dermatomyositis","volume":"61","author":"Karasawa","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R20-20261001","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/rheumatology\/kex468","article-title":"Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics","volume":"57","author":"Karasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R21-20261001","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/rheumatology\/kead203","article-title":"Association of anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis","volume":"62","author":"Karasawa","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20261001","doi-asserted-by":"crossref","first-page":"103332","DOI":"10.1016\/j.jaut.2024.103332","article-title":"Autoantibodies against a subunit of mitochondrial respiratory chain complex I in inclusion body myositis","volume":"149","author":"Notarnicola","year":"2024","journal-title":"J Autoimmun"},{"key":"R23-20261001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"R24-20261001","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S2213-2600(24)00267-4","article-title":"Idiopathic inflammatory myopathies related lung disease in adults","volume":"13","author":"Sehgal","year":"2025","journal-title":"Lancet Respir Med"},{"key":"R25-20261001","doi-asserted-by":"crossref","first-page":"104804","DOI":"10.1016\/j.ebiom.2023.104804","article-title":"Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies","volume":"96","author":"Leclair","year":"2023","journal-title":"EBioMedicine"},{"key":"R26-20261001","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.3390\/ijms252011061","article-title":"Increased cytokine levels in seronegative myositis: potential Th17 immune response implications","volume":"25","author":"Aguilar-Vazquez","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R27-20261001","doi-asserted-by":"crossref","DOI":"10.1002\/art.42768","article-title":"Clinical features and immunogenetic risk factors associated with additional autoantibodies in anti-transcriptional intermediary factor 1gamma juvenile-onset dermatomyositis","volume":"76","author":"Sherman","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R28-20261001","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.molcel.2008.08.001","article-title":"CCAR1, a key regulator of mediator complex recruitment to nuclear receptor transcription complexes","volume":"31","author":"Kim","year":"2008","journal-title":"Mol Cell"},{"key":"R29-20261001","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.18632\/oncotarget.3376","article-title":"CARP-1\/CCAR1: a biphasic regulator of cancer cell growth and apoptosis","volume":"6","author":"Muthu","year":"2015","journal-title":"Oncotarget"},{"key":"R30-20261001","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1006\/dbio.1996.0134","article-title":"Sp4, a member of the Sp1-family of zinc finger transcription factors, is required for normal murine growth, viability, and male fertility","volume":"176","author":"Supp","year":"1996","journal-title":"Dev Biol"},{"key":"R31-20261001","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/art.42474","article-title":"Association of anti-CCAR1 autoantibodies with decreased cancer risk relative to the general population in patients with anti-transcriptional intermediary factor 1gamma-positive dermatomyositis","volume":"75","author":"Fiorentino","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R32-20261001","doi-asserted-by":"crossref","first-page":"e150201","DOI":"10.1172\/JCI150201","article-title":"Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence","volume":"132","author":"Fiorentino","year":"2022","journal-title":"J Clin Invest"},{"key":"R33-20261001","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/ard-2022-222441","article-title":"Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1gamma autoantibodies","volume":"82","author":"Hosono","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R34-20261001","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/art.42512","article-title":"Autoantibodies recognizing specificity protein 4 co-occur with anti-transcription intermediary factor 1 and are associated with distinct clinical features and immunogenetic risk factors in juvenile myositis","volume":"75","author":"Sherman","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R35-20261001","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/acr2.11750","article-title":"The relationship between anti-cell division cycle and apoptosis regulator 1 autoantibodies, anti-Sp4 autoantibodies, and cancer in anti-transcription intermediary factor 1gamma-positive dermatomyositis","volume":"6","author":"Mecoli","year":"2024","journal-title":"ACR Open Rheumatol"},{"key":"R36-20261001","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"R37-20261001","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1007\/s10067-025-07562-1","article-title":"Coexistence of antimelanoma differentiation-associated protein 5 and anti-Ro52 antibodies in patients with idiopathic inflammatory myopathy: a retrospective cohort study","volume":"44","author":"Chen","year":"2025","journal-title":"Clin Rheumatol"},{"key":"R38-20261001","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.42308","article-title":"Identification of three different phenotypes in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease","volume":"75","author":"Xu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R39-20261001","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1093\/rheumatology\/keae466","article-title":"Comparative B cell epitope profiling in Japanese and North American cohorts of MDA5+ dermatomyositis patients reveals a direct association between immune repertoire and pulmonary mortality","volume":"64","author":"Yamaguchi","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R40-20261001","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3949\/ccjm.92a.25018","article-title":"MDA5 dermatomyositis: unveiling a potentially life-threatening disease","volume":"92","author":"Chatterjee","year":"2025","journal-title":"Cleve Clin J Med"},{"key":"R41-20261001","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12931-026-03572-y","article-title":"Distinct anti-MDA5 antibody trajectories associated with long-term outcomes in 6-month survivors of anti-MDA5 dermatomyositis with interstitial lung disease","volume":"27","author":"Chen","year":"2026","journal-title":"Respir Res"},{"key":"R42-20261001","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/rheumatology\/keac229","article-title":"Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease","volume":"62","author":"Xu","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R43-20261001","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13023-025-03921-y","article-title":"Anti-MDA5 antibody IgG1 subtype is associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis","volume":"20","author":"Wu","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"R44-20261001","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","article-title":"Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy","volume":"56","author":"Stone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R45-20261001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13075-022-02745-6","article-title":"Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and antisynthetase syndrome","volume":"24","author":"Notarnicola","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"R46-20261001","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13075-023-03116-5","article-title":"Anti-Jo-1 autoantibodies: biomarkers of severity and evolution of the disease in antisynthetase syndrome","volume":"25","author":"Arcani","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"R47-20261001","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R48-20261001","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of antisignal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R49-20261001","doi-asserted-by":"crossref","first-page":"e739","DOI":"10.1212\/WNL.0000000000013176","article-title":"Dermatomyositis: muscle pathology according to antibody subtypes","volume":"98","author":"Tanboon","year":"2022","journal-title":"Neurology"},{"key":"R50-20261001","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ane.13331","article-title":"Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies","volume":"143","author":"Wong","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"R51-20261001","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1007\/s10067-022-06291-z","article-title":"Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China","volume":"41","author":"Wen","year":"2022","journal-title":"Clin Rheumatol"},{"key":"R52-20261001","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1084\/jem.190.6.815","article-title":"Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity","volume":"190","author":"Casciola-Rosen","year":"1999","journal-title":"J Exp Med"},{"key":"R53-20261001","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.4049\/jimmunol.143.7.2267","article-title":"Epitope mapping of the cloned human autoantigen, histidyl-tRNA synthetase. Analysis of the myositis-associated anti-Jo-1 autoimmune response","volume":"143","author":"Ramsden","year":"1989","journal-title":"J Immunol"},{"key":"R54-20261001","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/rheumatology\/kead400","article-title":"Autoantibodies against the melanoma differentiation-associated protein 5 in patients with dermatomyositis target the helicase domains","volume":"63","author":"Van Gompel","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R55-20261001","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/rheumatology\/kead397","article-title":"The central helicase domain holds the major conformational epitopes of melanoma differentiation-associated gene 5 autoantibodies","volume":"63","author":"Mo","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R56-20261001","doi-asserted-by":"crossref","first-page":"1735735","DOI":"10.3389\/fimmu.2026.1735735","article-title":"PhIP-Seq: unveiling the complexity of antibody repertoires in health and disease","volume":"17","author":"Tang","year":"2026","journal-title":"Front Immunol"},{"key":"R57-20261001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2026.103536","article-title":"Anti-MDA5 monoclonal antibodies from patients with dermatomyositis - B cell characteristics and differential targeting of the helicase domains","volume":"159","author":"Van Gompel","year":"2026","journal-title":"J Autoimmun"},{"key":"R58-20261001","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"R59-20261001","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.imlet.2014.11.001","article-title":"B cell epitope spreading: mechanisms and contribution to autoimmune diseases","volume":"163","author":"Cornaby","year":"2015","journal-title":"Immunol Lett"},{"key":"R60-20261001","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ard.2025.08.023","article-title":"Myositis-specific autoantibodies recognising Mi2 also target the AIRE protein at a shared PHD zinc finger","volume":"85","author":"Musai","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R61-20261001","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1093\/rheumatology\/keaf426","article-title":"Anti-Mi2 autoantibodies target PHD fingers of SP140L and TIF1gamma, while anti-TIF1gamma autoantibodies primarily bind TIF1gamma outside the PHD region","volume":"64","author":"Pinal-Fernandez","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R62-20261001","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.4049\/jimmunol.169.12.7127","article-title":"Critical requirement for professional APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis","volume":"169","author":"Ascherman","year":"2002","journal-title":"J Immunol"},{"key":"R63-20261001","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/art.41075","article-title":"Proinflammatory histidyl-transfer RNA synthetase-specific CD4+ T cells in the blood and lungs of patients with idiopathic inflammatory myopathies","volume":"72","author":"Galindo-Feria","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R64-20261001","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ard.2025.09.015","article-title":"Autoreactive T cells identified in patients with anti-Jo1+ antisynthetase syndrome recognise a new epitope on histidyl t-RNA synthetase","volume":"85","author":"Galindo-Feria","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"R65-20261001","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/annrheumdis-2019-215046","article-title":"Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups","volume":"78","author":"Rothwell","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R66-20261001","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/gene.2015.28","article-title":"Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes","volume":"16","author":"Miller","year":"2015","journal-title":"Genes Immun"},{"key":"R67-20261001","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.cell.2012.11.048","article-title":"Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5","volume":"152","author":"Wu","year":"2013","journal-title":"Cell"},{"key":"R68-20261001","first-page":"10","article-title":"VASP-mediated actin dynamics activate and recruit a filopodia myosin","author":"Arthur","year":"2021","journal-title":"Elife"},{"key":"R69-20261001","doi-asserted-by":"crossref","first-page":"743704","DOI":"10.3389\/fimmu.2021.743704","article-title":"RNA-containing immune complexes formed by anti-melanoma differentiation associated gene 5 autoantibody are potent inducers of IFN-alpha","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"R70-20261001","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.4049\/jimmunol.144.5.1737","article-title":"Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis","volume":"144","author":"Targoff","year":"1990","journal-title":"J Immunol"},{"key":"R71-20261001","doi-asserted-by":"crossref","first-page":"102680","DOI":"10.1016\/j.jaut.2021.102680","article-title":"Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera","volume":"122","author":"Muro","year":"2021","journal-title":"J Autoimmun"},{"key":"R72-20261001","doi-asserted-by":"crossref","first-page":"104032","DOI":"10.1016\/j.autrev.2026.104032","article-title":"Clinical characteristics and cancer risk of anti-OJ antisynthetase syndrome: a cohort comparative study and a systematic literature review","volume":"25","author":"Pillot","year":"2026","journal-title":"Autoimmun Rev"},{"key":"R73-20261001","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.autrev.2019.05.002","article-title":"Anti-OJ autoantibodies: rare or underdetected?","volume":"18","author":"Vulsteke","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R74-20261001","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","article-title":"Immune-mediated necrotizing myopathy: clinical features and pathogenesis","volume":"16","author":"Allenbach","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R75-20261001","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"R76-20261001","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1742-7843.2006.pto_193.x","article-title":"Muscle symptoms associated with statins: a series of twenty patients","volume":"98","author":"Soininen","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R77-20261001","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R78-20261001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/JND-170282","article-title":"Anti-HMGCR myopathy","volume":"5","author":"Mohassel","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"R79-20261001","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.ard.2025.04.027","article-title":"In immune-mediated necrotising myopathy, anti-HMGCR antibodies inhibit HMGCR activity, leading to the sarcoplasmic accumulation of lipid droplets and myofibres necrosis","volume":"84","author":"Giannini","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R80-20261001","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S1474-4422(25)00233-9","article-title":"Advances in the classification and management of idiopathic inflammatory myopathies","volume":"24","author":"Raaphorst","year":"2025","journal-title":"Lancet Neurol"},{"key":"R81-20261001","doi-asserted-by":"crossref","first-page":"118525","DOI":"10.1016\/j.biopha.2025.118525","article-title":"The pathogenesis of immune-mediated necrotizing myopathy: progress and therapeutic implications","volume":"191","author":"Yang","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"R82-20261001","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jneuroim.2013.08.008","article-title":"Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM)","volume":"264","author":"Rojana-udomsart","year":"2013","journal-title":"J Neuroimmunol"},{"key":"R83-20261001","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP(+) and anti-HMGCR(+)myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"R84-20261001","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of antisignal recognition protein and anti3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann Neurol"},{"key":"R85-20261001","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R86-20261001","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1084\/jem.20080091","article-title":"Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5","volume":"205","author":"Kato","year":"2008","journal-title":"J Exp Med"},{"key":"R87-20261001","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pharmthera.2009.06.012","article-title":"Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity","volume":"124","author":"Barral","year":"2009","journal-title":"Pharmacol Ther"},{"key":"R88-20261001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R89-20261001","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tim.2018.08.007","article-title":"A balancing act: MDA5 in Antiviral Immunity and Autoinflammation","volume":"27","author":"Dias Junior","year":"2019","journal-title":"Trends Microbiol"},{"key":"R90-20261001","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41577-020-0288-3","article-title":"RIG-I-like receptors: their regulation and roles in RNA sensing","volume":"20","author":"Rehwinkel","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"R91-20261001","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R92-20261001","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","article-title":"Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression","volume":"186","author":"Allenbach","year":"2016","journal-title":"Am J Pathol"},{"key":"R93-20261001","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/acn3.51311","article-title":"Mitochondrial morphology and MAVS-IFN1 signaling pathway in muscles of anti-MDA5 dermatomyositis","volume":"8","author":"Jiang","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"R94-20261001","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10067-017-3799-y","article-title":"Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis","volume":"37","author":"Peng","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R95-20261001","doi-asserted-by":"crossref","first-page":"134189","DOI":"10.1172\/jci.insight.134189","article-title":"Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies","volume":"5","author":"Seto","year":"2020","journal-title":"JCI Insight"},{"key":"R96-20261001","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1002\/art.22860","article-title":"A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52\/anti-Ro 60 autoantibodies","volume":"56","author":"Eloranta","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R97-20261001","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/art.42989","article-title":"TLR7\/8 activation in immune cells and muscle by RNA-containing immune complexes: role in inflammation and the pathogenesis of myositis","volume":"77","author":"Wu","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R98-20261001","doi-asserted-by":"crossref","first-page":"25537","DOI":"10.1038\/s41598-025-10895-1","article-title":"Dysregulated type I\/III interferon system in circulation from patients with anti-MDA5-positive dermatomyositis","volume":"15","author":"Yoshida","year":"2025","journal-title":"Sci Rep"},{"key":"R99-20261001","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R100-20261001","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaad.2010.08.004","article-title":"Enhanced skin expression of melanoma differentiation-associated gene 5 (MDA5) in dermatomyositis and related autoimmune diseases","volume":"64","author":"Zahn","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R101-20261001","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bjd.16917","article-title":"Aberrant activation of the type I interferon system may contribute to the pathogenesis of antimelanoma differentiation-associated gene 5 dermatomyositis","volume":"180","author":"Zhang","year":"2019","journal-title":"Br J Dermatol"},{"key":"R102-20261001","doi-asserted-by":"crossref","first-page":"773352","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"R103-20261001","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/cei.13404","article-title":"A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis","volume":"199","author":"Peng","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"R104-20261001","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.rmed.2015.07.004","article-title":"Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140\/MDA5 antibody positive amyopathic dermatomyositis","volume":"109","author":"Takada","year":"2015","journal-title":"Respir Med"},{"key":"R105-20261001","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/kez185","article-title":"Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD","volume":"58","author":"Horiike","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R106-20261001","doi-asserted-by":"crossref","first-page":"1151695","DOI":"10.3389\/fimmu.2023.1151695","article-title":"Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients","volume":"14","author":"Qian","year":"2023","journal-title":"Front Immunol"},{"key":"R107-20261001","doi-asserted-by":"crossref","first-page":"e2313070121","DOI":"10.1073\/pnas.2313070121","article-title":"Autoimmunity against melanoma differentiation-associated gene 5 induces interstitial lung disease mimicking dermatomyositis in mice","volume":"121","author":"Ichimura","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R108-20261001","doi-asserted-by":"crossref","first-page":"e65362","DOI":"10.1371\/journal.pone.0065362","article-title":"Type 1 interferons inhibit myotube formation independently of upregulation of interferon-stimulated gene 15","volume":"8","author":"Franzi","year":"2013","journal-title":"PLoS One"},{"key":"R109-20261001","doi-asserted-by":"crossref","first-page":"e2108","DOI":"10.1212\/WNL.0000000000200271","article-title":"Involvement of type I interferon signaling in muscle stem cell proliferation during dermatomyositis","volume":"98","author":"Gallay","year":"2022","journal-title":"Neurology"},{"key":"R110-20261001","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R111-20261001","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1136\/ard-2023-223873","article-title":"Transcriptional derepression of CHD4\/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies","volume":"82","author":"Pinal-Fernandez","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R112-20261001","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/304177a0","article-title":"Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity","volume":"304","author":"Mathews","year":"1983","journal-title":"Nature"},{"key":"R113-20261001","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.3390\/diagnostics13193080","article-title":"Detection of myositis autoantibodies by multi-analytic immunoassays in a large multicenter cohort of patients with definite idiopathic inflammatory myopathies","volume":"13","author":"Ghirardello","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R114-20261001","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1097\/RHU.0000000000002043","article-title":"Analytic and clinical validity of myositis-specific antibodies by line-blot immunoassay is essential","volume":"30","author":"Tseng","year":"2024","journal-title":"J Clin Rheumatol"},{"key":"R115-20261001","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/1756-185X.14174","article-title":"Performance of myositis-specific antibodies detected on myositis line immunoassay to diagnose and sub-classify patients with suspected idiopathic inflammatory myopathy, a retrospective records-based review","volume":"24","author":"Beaton","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"R116-20261001","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1007\/s10067-026-08153-4","article-title":"Optimizing line blot assays: impact of band intensity adjustment on diagnostic performance in myositis autoantibodies testing","volume":"45","author":"Huttmann","year":"2026","journal-title":"Clin Rheumatol"},{"key":"R117-20261001","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/diagnostics13010156","article-title":"Deciphering the autoantibody response to the OJ antigenic complex","volume":"13","author":"Fritzler","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R118-20261001","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1515\/cclm-2026-0179","article-title":"Comprehensive assessment of innovative immunoassays for the detection of myositis specific antibodies","volume":"64","author":"Rimann-Langejuergen","year":"2026","journal-title":"Clin Chem Lab Med"},{"key":"R119-20261001","doi-asserted-by":"crossref","first-page":"113876","DOI":"10.1016\/j.jim.2025.113876","article-title":"Deciphering the autoreactome: massively parallelized methods for autoantibody detection in humans","volume":"541","author":"Horstke","year":"2025","journal-title":"J Immunol Methods"},{"key":"R120-20261001","doi-asserted-by":"crossref","first-page":"103548","DOI":"10.1016\/j.jaut.2026.103548","article-title":"Interlaboratory variability in laboratory testing and reporting of myositis autoantibodies","volume":"160","author":"Harvey","year":"2026","journal-title":"J Autoimmun"},{"key":"R121-20261001","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/rheumatology\/keae167","article-title":"Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort","volume":"63","author":"Loganathan","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R122-20261001","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fimmu.2015.00412","article-title":"Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns","volume":"6","author":"Chan","year":"2015","journal-title":"Front Immunol"},{"key":"R123-20261001","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/annrheumdis-2018-214436","article-title":"Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective","volume":"78","author":"Damoiseaux","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R124-20261001","doi-asserted-by":"crossref","first-page":"102588","DOI":"10.1016\/j.autrev.2020.102588","article-title":"A new diagnostic algorithm for pattern-oriented autoantibody testing according to the ICAP nomenclature: a pilot study","volume":"19","author":"Infantino","year":"2020","journal-title":"Autoimmun Rev"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:02:03Z","timestamp":1790834523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0000000000001195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":124,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001195","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}